1. Home
  2. NERV vs IMRX Comparison

NERV vs IMRX Comparison

Compare NERV & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$5.31

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.34

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NERV
IMRX
Founded
2007
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.6M
340.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
NERV
IMRX
Price
$5.31
$5.34
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$10.50
$17.20
AVG Volume (30 Days)
129.8K
691.2K
Earning Date
05-01-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.75
EPS
N/A
N/A
Revenue
$41,175,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$1.57
52 Week High
$12.46
$10.08

Technical Indicators

Market Signals
Indicator
NERV
IMRX
Relative Strength Index (RSI) 42.85 52.97
Support Level $5.02 $5.31
Resistance Level $6.69 $5.80
Average True Range (ATR) 0.42 0.36
MACD -0.07 -0.00
Stochastic Oscillator 46.96 26.68

Price Performance

Historical Comparison
NERV
IMRX

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: